Core Viewpoint - Renal anemia is a common complication in chronic kidney disease (CKD) patients, and understanding its mechanisms, diagnosis, treatment, and management is crucial for improving patient outcomes [2][3][4][5][6] Group 1: Mechanism and Impact of Renal Anemia - Renal anemia is primarily linked to impaired kidney function, leading to reduced erythropoietin (EPO) production, which in turn suppresses bone marrow activity and decreases red blood cell production [2] - Accumulation of uremic toxins further destabilizes red blood cell membranes, shortening their lifespan and exacerbating anemia [2] - If not addressed, chronic anemia can result in tissue hypoxia, accelerating kidney function decline and increasing cardiovascular risks, including left ventricular hypertrophy and heart failure [2] Group 2: Diagnosis and Treatment Principles - Diagnosis of renal anemia involves assessing hemoglobin levels, with thresholds set at <130 g/L for men and <120 g/L for non-pregnant women [3] - Treatment goals aim to maintain hemoglobin levels between 110-130 g/L, correcting reversible factors like iron deficiency and infections [3] - Early diagnosis and treatment are emphasized to improve quality of life and reduce hospitalization and dialysis needs [3] Group 3: Advances in HIF-PHI Drug Therapy - Traditional treatments for renal anemia rely on injected EPO and iron supplements, which may lead to reduced efficacy over time due to antibody formation [4] - HIF-PHI drugs represent a significant advancement, offering oral administration that enhances patient compliance and reduces treatment burden [4] - These drugs not only stimulate endogenous EPO production but also improve iron absorption and counteract chronic inflammation's negative effects on hematopoiesis [4] Group 4: Daily Management and Self-Monitoring - Effective long-term management of renal anemia requires lifestyle adjustments, including a diet rich in iron and vitamin C, moderate exercise, and regular monitoring of hemoglobin and iron levels [5] - Patients are advised to consume iron-rich foods while avoiding substances like tea and coffee that can inhibit iron absorption [5] - Regular check-ups are recommended, with intervals adjusted based on treatment status to ensure timely modifications to therapy [5] Group 5: Future Directions and Public Awareness - Despite advancements in treatment, there remains room for improvement in achieving target hemoglobin levels among patients in China [6] - Increased public education and standardized treatment protocols are essential for enhancing patient quality of life and reducing complications [6] - Regular screening for anemia in CKD patients is crucial for early detection and management [6]

Core Viewpoint - Renal anemia is a common complication in chronic kidney disease (CKD) patients, significantly affecting their quality of life and increasing the risk of cardiovascular events and mortality [1] Group 1: Disease Overview - Approximately 50% of CKD patients in China experience anemia, with incidence rates rising as kidney function deteriorates [1] - The underlying causes of renal anemia include insufficient erythropoietin (EPO) production, iron metabolism disorders, and inflammation [1] - Symptoms of renal anemia include fatigue, palpitations, and reduced exercise tolerance [1] Group 2: Treatment Challenges - Current treatment options include iron supplementation, erythropoiesis-stimulating agents (ESA), and oral HIF-PHI drugs [1] - Patients face challenges such as iron deficiency, ESA resistance, and poor treatment adherence [1] - Some patients delay diagnosis and treatment due to a lack of awareness or reliance on blood transfusions [1] Group 3: Expert Insights - A live session featuring experts in nephrology will be held to discuss the standardized diagnosis and treatment of renal anemia, aiming to help patients and families respond scientifically and improve quality of life [1][2]